RU2015131467A3 - - Google Patents

Download PDF

Info

Publication number
RU2015131467A3
RU2015131467A3 RU2015131467A RU2015131467A RU2015131467A3 RU 2015131467 A3 RU2015131467 A3 RU 2015131467A3 RU 2015131467 A RU2015131467 A RU 2015131467A RU 2015131467 A RU2015131467 A RU 2015131467A RU 2015131467 A3 RU2015131467 A3 RU 2015131467A3
Authority
RU
Russia
Application number
RU2015131467A
Other languages
Russian (ru)
Other versions
RU2672910C2 (ru
RU2672910C9 (ru
RU2015131467A (ru
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/016643 external-priority patent/WO2014130375A1/en
Publication of RU2015131467A publication Critical patent/RU2015131467A/ru
Publication of RU2015131467A3 publication Critical patent/RU2015131467A3/ru
Publication of RU2672910C2 publication Critical patent/RU2672910C2/ru
Application granted granted Critical
Publication of RU2672910C9 publication Critical patent/RU2672910C9/ru

Links

RU2015131467A 2013-02-21 2014-02-15 Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы RU2672910C9 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361767721P 2013-02-21 2013-02-21
US61/767,721 2013-02-21
PCT/US2014/016643 WO2014130375A1 (en) 2013-02-21 2014-02-15 Heteroaromatic compounds as pi3 kinase modulators

Publications (4)

Publication Number Publication Date
RU2015131467A RU2015131467A (ru) 2017-03-24
RU2015131467A3 true RU2015131467A3 (enExample) 2018-01-26
RU2672910C2 RU2672910C2 (ru) 2018-11-21
RU2672910C9 RU2672910C9 (ru) 2019-06-04

Family

ID=51351332

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015131467A RU2672910C9 (ru) 2013-02-21 2014-02-15 Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы

Country Status (14)

Country Link
US (1) US9573953B2 (enExample)
EP (1) EP2958564B1 (enExample)
JP (1) JP6389829B2 (enExample)
KR (1) KR102148681B1 (enExample)
AU (1) AU2014219256B2 (enExample)
BR (1) BR112015018318A2 (enExample)
CA (1) CA2898294C (enExample)
ES (1) ES2674705T3 (enExample)
MX (1) MX2015010700A (enExample)
MY (1) MY182036A (enExample)
RU (1) RU2672910C9 (enExample)
SG (1) SG11201505493QA (enExample)
TW (1) TWI620749B (enExample)
WO (1) WO2014130375A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Cdk8調節およびその適応症のための化合物および方法
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018169700A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CN109867671B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867669B (zh) * 2017-12-02 2021-02-26 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867670B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的单钠盐及其医药用途
CN109867672B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 吡唑[1,5-a]吡啶衍生物的盐及其用途
CN109867668B (zh) * 2017-12-02 2021-03-26 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
US11179376B2 (en) * 2017-12-20 2021-11-23 Sunshine Lake Pharma Co., Ltd. Salts of pyrazolo[1,5-a]pyridine derivative and use thereof
CN112770757B (zh) * 2018-10-19 2024-01-16 广东东阳光药业股份有限公司 一种治疗纤维化疾病的药物组合或药物组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
DE69417918T2 (de) 1993-11-30 2000-01-05 Mcgill University, Montreal Dna methyltransferase inhibierung
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
KR20020007398A (ko) 1999-05-03 2002-01-26 추후제출 히스톤 탈아세틸화효소의 억제
KR20100035666A (ko) 1999-11-23 2010-04-05 메틸진 인크. 히스톤 디아세틸라제의 억제제
JP2003528074A (ja) 2000-03-24 2003-09-24 メチルジーン インコーポレイテッド ヒストン脱アセチル化酵素の阻害剤
EP2093292A2 (en) 2000-03-24 2009-08-26 Methylgene, Inc. Inhibition of specific histone deacetylase isoforms
BR0209252A (pt) * 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
CA2465978C (en) 2001-09-14 2015-04-07 Soon Hyung Woo Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1551795A1 (en) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
US7550470B2 (en) * 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
ES2222813B1 (es) * 2003-07-24 2005-12-16 Ferrer Internacional, S.A. N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados.
AU2004276337B2 (en) 2003-09-24 2009-11-12 Methylgene Inc. Inhibitors of histone deacetylase
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
AU2005225471B2 (en) 2004-03-26 2011-05-12 Methylgene Inc. Inhibitors of histone deacetylase
EP1781664B1 (en) 2004-07-30 2013-09-04 MethylGene Inc. Inhibitors of vegf receptor and hgf receptor signaling
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
JP2011500823A (ja) * 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
UA111579C2 (uk) * 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
US8883801B2 (en) * 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
CN102675286B (zh) 2011-03-07 2015-08-19 中国科学院上海药物研究所 一类吲唑类化合物及其制备方法、用途和药物组合物
AU2012257513B2 (en) * 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
KR101274986B1 (ko) 2011-07-27 2013-06-17 한국과학기술원 이미다조피리딘 유도체, 이를 포함하는 PI3K 및/또는 mTOR 저해제용 약학 조성물 및 PI3K 및/또는 mTOR과 연관된 질환 치료용 약학 조성물
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN102924450A (zh) 2012-11-01 2013-02-13 西安交通大学 6-(5-吡啶基)-1,2,4-三唑并吡啶类化合物及其制备方法和用途

Similar Documents

Publication Publication Date Title
BR112021000792B8 (enExample)
AT524874A5 (enExample)
AT524834A2 (enExample)
AU2018438767B1 (enExample)
AT521543A3 (enExample)
AT524961A5 (enExample)
AT524266A2 (enExample)
BR102019026286B1 (pt) Método e aparelho para o avanço de produtos a serem moldados
BR102019025884B1 (pt) Sistema de segurança aprimorado para máquinas de operação de autopropulsão
BR102019023514B1 (pt) Método para determinar a massa de ar preso em cada cilindro de um motor a combustão interna
BR112021001434B1 (pt) Aço com alto teor de manganês e método de produção do mesmo
BR112021001374B1 (pt) Composição farmacêutica para o tratamento da hipertensão e seu uso
BR112021001128B1 (pt) Composição de cimento para impressão 3d, método de impressão 3d, kit para a preparação de uma composição de cimento para impressão 3d e método de impressão 3d implementando o kit
BR112021001186B1 (pt) Aparelho para o tratamento de celulite para tratar expressões de celulite na pele de um paciente associadas a um local de tratamento de septos
BR112020023795B1 (pt) Composição de recheio para um produto de chocolate à base de gordura, e seus métodos de produção
BR112021000922B1 (pt) Tela de filtro, e, método para purificar água de alimentação
BR112020026077B1 (pt) Recipiente com estrutura encaixável
BR112020023832B1 (pt) Amostra de calibração de sistemas de análise multiespectral e método para calibração de sistemas de análise multiespectral
BR112020024987B1 (pt) Método, montagem e sistema para prover uma estrutura de base, método industrial, e, braço mecânico
BR112020023823B1 (pt) Distribuidor
BR112020022482B1 (pt) Composição, anticorpo anti-cd24, anticorpo biespecífico e receptor de antígeno quimérico
BR112020022658B1 (pt) Método para estimar um nível de pressão sonora, sistema de fone de ouvido, fone de ouvido e uso do fone de ouvido
BR112020022516B1 (pt) Processo para degomagem enzimática de óleo
BR112020021042B1 (pt) Compostos de carboxamidas bicíclicas, composição farmacêutica e uso das mesmas
BR112020020812B1 (pt) Composições de tratamento de superfícies duras, seu uso, método para proporcionar ação antimicrobiana residual e substrato relacionado